The predictive value of the HALP score for no-reflow phenomenon and short-term mortality in patients with ST-elevation myocardial infarction

References

• Whisenant BK, Wolfe CL. Acute myocardial infarction. Recommendations for medical management and primary angioplasty. Postgrad Med. 1997 Sep;102(3):159–160, 163–168, 170–172. passim. PMID: 9300025. doi: 10.3810/pgm.1997.09.319
   Web of Science ®Google Scholar
• Kalra S, Duggal S, Valdez G, et al. Review of acute coronary syndrome diagnosis and management. Postgrad Med. 2008 Apr;120(1):18–27. PMID: 18467805. doi: 10.3810/pgm.2008.04.1756
   PubMed Web of Science ®Google Scholar
• Roe MT, Kikano G, Miller CD, et al. Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition. Postgrad Med. 2008 Jul;120(2):67–78. PMID: 18654071. doi: 10.3810/pgm.2008.07.1793
   PubMed Web of Science ®Google Scholar
• Niccoli G, Cosentino N, Spaziani C, et al. No-reflow: incidence and detection in the cath-lab. Curr Pharm Des. 2013;19(25):4564–4575. PMID: 23270553. doi: 10.2174/1381612811319250005
   PubMed Web of Science ®Google Scholar
• Ciofani JL, Allahwala UK, Scarsini R, et al. No-reflow phenomenon in ST-segment elevation myocardial infarction: still the Achilles’ heel of the interventionalist. Future Cardiol. 2021 Mar;17(2):383–397. Epub 2020 Sep 11. PMID: 32915083. doi: 10.2217/fca-2020-0077
   PubMed Web of Science ®Google Scholar
• Rezkalla SH, Stankowski RV, Hanna J, et al. Management of No-reflow phenomenon in the catheterization laboratory. JACC: Cardiovasc Interv. 2017 Feb 13;10(3):215–223. Erratum in: JACC Cardiovasc Interv. 2017 Jun 26;10(12):1282. PMID: 28183461. doi: 10.1016/j.jcin.2016.11.059
   PubMed Web of Science ®Google Scholar
• Pantea-Roșan LR, Pantea VA, Bungau S, et al. No-reflow after PPCI-A predictor of short-term outcomes in STEMI patients. J Clin Med. 2020 Sep 12;9(9):2956. PMID: 32932736; PMCID: PMC7563881. doi: 10.3390/jcm9092956
   PubMed Web of Science ®Google Scholar
• Papapostolou S, Andrianopoulos N, Duffy SJ, et al. Long-term clinical outcomes of transient and persistent no-reflow following percutaneous coronary intervention (PCI): a multicentre Australian registry. EuroIntervention. 2018 Jun 20;14(2):185–193. PMID: 28966156. doi: 10.4244/EIJ-D-17-00269
   PubMed Web of Science ®Google Scholar
• Kaur G, Baghdasaryan P, Natarajan B, et al. Pathophysiology, diagnosis, and management of coronary No-reflow phenomenon. Int J Angiol. 2021 Mar;30(1):15–21. Epub 2021 Mar 3. PMID: 34025092; PMCID: PMC8128485. doi: 10.1055/s-0041-1725979
   PubMedGoogle Scholar
• Allencherril J, Jneid H, Atar D, et al. Pathophysiology, diagnosis, and management of the No-reflow phenomenon. Cardiovasc Drugs Ther. 2019 Oct;33(5):589–597. PMID: 31418141. doi: 10.1007/s10557-019-06901-0
   PubMed Web of Science ®Google Scholar
• Kumar R, Khan KA, Shah JA, et al. Quantification of thrombus burden as an independent predictor of intra-procedural no-reflow in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary revascularization. J Ayub Med Coll Abbottabad. 2022 Apr;34(2):288–294. PMID: 35576288. doi: 10.55519/JAMC-02-9698
   PubMedGoogle Scholar
• Niccoli G, Lanza GA, Spaziani C, et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol. 2007 May 2;117(3):306–311. Epub 2006 Jul 21. PMID: 16859772. doi: 10.1016/j.ijcard.2006.05.012
   PubMed Web of Science ®Google Scholar
• Akbar KMA, Dharma S, Andriantoro H, et al. Relationship between hemoglobin concentration at admission with the incidence of no-reflow phenomenon and In-hospital mortality in acute myocardial infarction with elevation of ST segments in patients who underwent primary percutaneous coronary intervention. Int J Angiol. 2022 Feb 12;32(2):106–112. PMID: 37207009; PMCID: PMC10191690. doi: 10.1055/s-0042-1742308
   PubMedGoogle Scholar
• Zhao Y, Yang J, Ji Y, et al. Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Heart Vessels. 2019 Oct;34(10):1600–1607. Epub 2019 Apr 16. PMID: 30993442. doi: 10.1007/s00380-019-01399-w
   PubMed Web of Science ®Google Scholar
• Badran HM, Fatah AA, Soltan G. Platelet/Lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention. J Clin Trans Res. 2020 Jul 8;6(1):20–26. PMID: 32935070; PMCID: PMC7486979. doi: 10.18053/jctres.06.202001.004
   Google Scholar
• Stajic Z, Milicevic D, Kafedzic S, et al. Predicting no-reflow phenomenon prior to primary percutaneous coronary intervention using a novel probability risk score derived from clinical and angiographic parameters. Eur Rev Med Pharmacol Sci. 2022 Feb;26(3):759–770. PMID: 35179742. doi: 10.26355/eurrev_202202_27984
   PubMed Web of Science ®Google Scholar
• Dai C, Liu M, Zhou Y, et al. A score system to predict no-reflow in primary percutaneous coronary intervention: the PIANO score. Eur J Clin Invest. 2022 Feb;52(2):e13686. Epub 2021 Oct 11. PMID: 34596236. doi: 10.1111/eci.13686
   PubMed Web of Science ®Google Scholar
• Wang JW, Zhou ZQ, Chen YD, et al. A risk score for no reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Clin Cardiol. 2015 Apr;38(4):208–215. Epub 2015 Apr 16. PMID: 25892404; PMCID: PMC6711063. doi: 10.1002/clc.22376
   PubMed Web of Science ®Google Scholar
• Antar R, Farag C, Xu V, et al. Evaluating the baseline hemoglobin, albumin, lymphocyte, and platelet (HALP) score in the United States adult population and comorbidities: an analysis of the NHANES. Front Nutr. 2023 May 18;10:1206958. PMID: 37284646; PMCID: PMC10240525. doi: 10.3389/fnut.2023.1206958
   PubMed Web of Science ®Google Scholar
• Pan H, Lin S. Association of hemoglobin, albumin, lymphocyte, and platelet score with risk of cerebrovascular, cardiovascular, and all-cause mortality in the general population: results from the NHANES 1999-2018. Front Endocrinol. 2023 Jun 23;14: 1173399. PMID: 37424853; PMCID: PMC10328756. doi: 10.3389/fendo.2023.1173399
   PubMed Web of Science ®Google Scholar
• Karakayali M, Omar T, Artac I, et al. The prognostic value of HALP score in predicting in-hospital mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2023 Nov 1;34(7):483–488. Epub 2023 Jul 28. PMID: 37799045. doi: 10.1097/MCA.0000000000001271
   PubMed Web of Science ®Google Scholar
• Kocaoglu S, Alatli T. The efficiency of the HALP score and the modified HALP score in predicting mortality in patients with acute heart failure presenting to the emergency department. J Coll Physicians Surg Pak. 2022 Jun;32(6):706–711. PMID: 35686400. doi: 10.29271/jcpsp.2022.06.706
   PubMed Web of Science ®Google Scholar
• Dehmer GJ, Badhwar V, Bermudez EA, et al. 2020 AHA/ACC key data elements and definitions for coronary revascularization: a report of the American college of cardiology/American heart association task force on clinical data standards (writing committee to develop clinical data standards for coronary revascularization). J Am Coll Cardiol. 2020 Apr 28;75(16):1975–2088. Epub 2020 Mar 23. PMID: 32217040. doi: 10.1016/j.jacc.2020.02.010
   PubMed Web of Science ®Google Scholar
• Gibson CM, de Lemos JA, Murphy SA, et al., TIMI Study Group. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29;103(21):2550–2554. PMID: 11382722. doi: 10.1161/01.cir.103.21.2550
   PubMed Web of Science ®Google Scholar
• Gibson CM, Cannon CP, Murphy SA, et al., TIMI Study Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002 Apr 23;105(16):1909–1913. PMID: 11997276. doi: 10.1161/01.cir.0000014683.52177.b5
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Executive group on behalf of the joint European society of cardiology (esc)/American college of cardiology (Acc)/American heart association (Aha)/world heart federation (WHF) task force for the universal definition of myocardial infarction. Fourth universal definition of myocardial infarction (2018). Circulation. 2018 Nov 13;138(20):e618–e651. Erratum in: Circulation. 2018 Nov 13;138(20):e652. PMID: 30571511. doi: 10.1161/CIR.0000000000000617
   PubMed Web of Science ®Google Scholar
• Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009 Jul 21;54(4):281–292. PMID: 19608025. doi: 10.1016/j.jacc.2009.03.054
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Chilian W, Crea F, et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res. 2019 Jun 1;115(7):1143–1155. PMID: 30428011; PMCID: PMC6529918. doi: 10.1093/cvr/cvy286
   PubMed Web of Science ®Google Scholar
• Magro M, Springeling T, van Geuns RJ, et al. Myocardial ‘no-reflow’ prevention. Curr Vasc Pharmacol. 2013 Mar 1;11(2):263–277. PMID: 23506503. doi: 10.2174/1570161111311020014
   PubMed Web of Science ®Google Scholar
• Toprak K, Kaplangoray M, Memioğlu T, et al. The HbA1c/C-Peptide ratio is associated with the no-reflow phenomenon in patients with ST-Elevation myocardial infarction. Angiology. 2023 Nov;3:33197231213166. Epub ahead of print. PMID: 37920902. doi: 10.1177/00033197231213166
   Google Scholar
• Kaplangoray M, Toprak K, Cicek, et al. Relação entre a Relação Fibrinogênio/Albumina e a Perfusão Microvascular em Pacientes Submetidos à Intervenção Coronária Percutânea Primária para Infarto do Miocárdio com Elevação do Segmento ST: Um Estudo Prospectivo. Arq Bras Cardiol. 2023;120(11):e20230002. doi: 10.36660/abc.20230002
   PubMedGoogle Scholar
• Toprak K, Kaplangoray M, Akyol S, et al. The non-HDL-C/HDL-C ratio is a strong and independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction. Acta Cardiol. 2024 Jan;4:1–12. Epub ahead of print. PMID: 38174719. doi: 10.1080/00015385.2023.2299102
   Google Scholar
• Xu H, Zheng X, Ai J, et al. Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients. Int Immunopharmacol. 2023 Jan;114:109496. Epub 2022 Nov 30. PMID: 36462339. doi: 10.1016/j.intimp.2022.109496
   PubMed Web of Science ®Google Scholar
• Xu SS, Li S, Xu HX, et al. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. World J Gastroenterol. 2020 Feb 28;26(8):828–838. PMID: 32148380; PMCID: PMC7052532. doi: 10.3748/wjg.v26.i8.828
   PubMed Web of Science ®Google Scholar
• Shen XB, Zhang YX, Wang W, et al. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score in patients with small cell lung cancer before first-line treatment with etoposide and progression-free survival. Med Sci Monit. 2019 Jul 29;25:5630–5639. PMID: 31356586; PMCID: PMC6685331. doi: 10.12659/MSM.917968
   PubMed Web of Science ®Google Scholar
• Tian M, Li Y, Wang X, et al. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is associated with poor outcome of acute ischemic stroke. Front Neurol. 2021 Jan 12;11:610318. PMID: 33510706; PMCID: PMC7835486. doi: 10.3389/fneur.2020.610318
   PubMed Web of Science ®Google Scholar
• Roche M, Rondeau P, Singh NR, et al. The antioxidant properties of serum albumin. FEBS Lett. 2008 Jun 11;582(13):1783–1787. Epub 2008 May 12. PMID: 18474236. doi: 10.1016/j.febslet.2008.04.057
   PubMed Web of Science ®Google Scholar
• Sheinenzon A, Shehadeh M, Michelis R, et al. Serum albumin levels and inflammation. Int j biol macromol. 2021 Aug 1;184:857–862. Epub 2021 Jun 25. PMID: 34181998. doi: 10.1016/j.ijbiomac.2021.06.140
   PubMed Web of Science ®Google Scholar
• Menzely T, Zukermann R, Shehadeh F, et al. Type of anemia, chronic non-cardiovascular illnesses, and outcomes of patients with ST-segment elevation myocardial infarction. Rambam Maimonides Med J. 2020 Apr 29;11(2):e0011. PMID: 32374259; PMCID: PMC7202449. doi: 10.5041/RMMJ.10397
   PubMed Web of Science ®Google Scholar
• Binti NN, Ferdausi N, Anik MEK, et al. Association of albumin, fibrinogen, and modified proteins with acute coronary syndrome. PloS One. 2022 Jul 26;17(7):e0271882. PMID: 35881574; PMCID: PMC9321412. doi: 10.1371/journal.pone.0271882
   PubMed Web of Science ®Google Scholar
• Dong G, Huang A, Liu L. Platelet-to-lymphocyte ratio and prognosis in STEMI: a meta-analysis. Eur J Clin Invest. 2021 Mar;51(3):e13386. Epub 2020 Sep 25. PMID: 32810283. doi: 10.1111/eci.13386
   PubMed Web of Science ®Google Scholar
• Toprak K, Özen K, Memioğlu T, et al. Comparison of the effect of uric acid/albumin ratio on coronary slow flow with other inflammation-based markers. Biomarker Med. 2024 Feb 7. doi: 10.2217/bmm-2023-0386.
   Web of Science ®Google Scholar